se·je·las
/ˌ səjəˈlas /
Origin: Malay
Adjective: clear, transparent, luminous, translucent
Sejelas is a recruitment consultancy offering bespoke talent acquisition services for the finance and life science industries.
Whether you are a company that needs help hiring the right people or a professional looking to advance your career, we are committed to supporting you with your search.
se·je·las
/ˌ səjəˈlas /
Origin: Malay
Adjective: clear, transparent, luminous, translucent
Sejelas is a recruitment consultancy offering bespoke talent acquisition services for the Life Science and Finance industries.
Whether you are a company that needs help hiring the right people or a professional looking to advance your career, we are committed to supporting you with your search.
se·je·las
/ˌ səjəˈlas /
Origin: Malay
Adjective: clear, transparent, luminous, translucent
Your Partner in Life Science & Finance Recruitment
What we do
We are the right partner to help recruit primarily in the following areas:
EXECUTIVE SEARCH
Recruiting the right executive leader can be one of the most challenging tasks a company can face.
Whether searching for Board Members, C-Level Officers or Senior Management, our well-maintained network and personal approach ensures our clients will have access to a diverse blend of skills and experience that matches the strategic direction of their organisations.
We serve a wide variety of companies from early stage start-ups to large public companies.
Life Sciences
Translational Research, R&D Project Management, Clinical Development & Operations, Medicinal Chemistry, Discovery Biology, Bio-Cheminformatics, Toxicology, Data Science, Business Intelligence, Digital Transformation, Digital Health, Commercial, Marketing, Sales, Business Development, Market Access, Medical Affairs
Finance
Investment Analysis and Management, Controlling, Mergers & Acquisitions, Corporate Finance, Strategy, Corporate Development, Risk Management, Transformation, Restructuring, Investor Relations, Controlling, Accounting, Financial Planning & Analysis, Audit, Human Resource, Recruitment, Operations
Clients
What do our customers say?
Making your next career move is an important step
We pride ourselves in supporting you to find the right opportunity that fulfills your ambitions, allowing you to make the right change, at the right time, to the right place.
Insights
The latest interviews and articles from Sejelas
Bo Rode Hansen
Tell us more about your background. Throughout my career, I have focused and been involved in creating, driving and transacting on innovation in medicine. I have led innovation and drug discovery with different technologies including RNA therapeutics, genetic medicines, drug delivery, informatics, biologics and small molecules. During your tenure as President & CEO at Scandion Oncology and Genevant Sciences, what were some of the most innovative projects you spearheaded, and what impact did they have on the company’s direction? As President & CEO at Scandion Oncology, I led the strategic transformation and growth of the company, raising 300 million SEK and listing the company on Nasdaq First North in Stockholm. This allowed Scandion to continue the development in Phase 2 and build the team. We focused on strategically positioning an inhibitor of an efflux pump in cancer cells as innovative projects designed to overcome cancer drug resistance – mainly in colorectal cancer and pancreatic cancer. The medical need in cancer for innovative projects is huge and resistance to existing therapies is the leading cause of the almost innumerable 10 million casualties to cancer every year.
Jana Fischer
Tell us about your background. My background is in computational biology and bioinformatics, which I studied at ETH Zürich. I then went on to combine my fascination for cancer research and my data analysis skills and joined the research group of Prof. Bernd Bodenmiller for my PhD. We used highly multiplex tissue imaging in order to characterize tumors and better understand their biology, the different tumor subtypes and the complex interactions between tumor and immune cells. Throughout my PhD I analyzed datasets of large patient cohorts and was able to show the remarkable potential of this type of data in explaining different patient outcomes such as drug response or survival.
